We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Roche Holding Ag | LSE:0QQ6 | London | Ordinary Share | CH0012032113 | ROCHE HOLDING ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 0.00 | 0.00% | 229.20 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 651 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 58.72B | 11.5B | - | N/A | 0 |
| Date | Time | Source | Headline |
|---|---|---|---|
| 19/12/2024 | 06:00 | UKREG | Roche’s Phase IIb study of prasinezumab missed primary endpoint, but.. |
| 18/12/2024 | 06:00 | UKREG | Roche transforms mass spectrometry diagnostics with launch of cobas® Mass.. |
| 13/12/2024 | 06:10 | UKREG | Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three.. |
| 13/12/2024 | 06:00 | UKREG | Roche receives CE Mark for new and updated molecular cobas 6800/8800.. |
| 10/12/2024 | 06:00 | UKREG | New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH.. |
| 09/12/2024 | 21:30 | UKREG | Roche commences tender offer for all shares of Poseida Therapeutics, Inc... |
| 08/12/2024 | 17:30 | UKREG | Five-year results confirm Roche’s Polivy combination therapy as new.. |
| 05/12/2024 | 06:00 | UKREG | FDA accepts supplemental Biologics License Application for Roche’s Columvi.. |
| 26/11/2024 | 06:10 | UKREG | Roche enters into a definitive agreement to acquire Poseida Therapeutics,.. |
| 26/11/2024 | 06:00 | UKREG | Roche reports update on Phase III SKYSCRAPER-01 study results |
1 Year Roche Chart |
Intraday Roche Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
